217 related articles for article (PubMed ID: 28460432)
1. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
Huang W; Zhou W; Li C; Yang Y; Shang YK; Chen C; Zhang J; Yao R; Wang P; Wen W; Liu HQ; Wang L; Li X; Bian H; Chen ZN
Oncotarget; 2017 Apr; 8(16):26288-26297. PubMed ID: 28460432
[TBL] [Abstract][Full Text] [Related]
2. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
5. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
6. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
9. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
[TBL] [Abstract][Full Text] [Related]
10. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
11. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
[TBL] [Abstract][Full Text] [Related]
12. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
13. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of PinX1 in human hepatocellular carcinoma.
Oh BK; Chae KJ; Park C; Park YN
Oncol Rep; 2004 Oct; 12(4):861-6. PubMed ID: 15375513
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma.
Kwa WT; Effendi K; Yamazaki K; Kubota N; Hatano M; Ueno A; Masugi Y; Sakamoto M
Pathol Int; 2020 Sep; 70(9):624-632. PubMed ID: 32559017
[TBL] [Abstract][Full Text] [Related]
20. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
